Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression

BACKGROUND: Rilotumumab, an investigational, monoclonal antibody, inhibits MET-mediated signalling. In a randomized phase 2 trial of rilotumumab±epirubicin/cisplatin/capecitabine in gastric or oesophagogastric junction cancer, patients receiving rilotumumab showed a trend towards improved survival,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Zhu, M, Tang, R, Doshi, S, Oliner, K S, Dubey, S, Jiang, Y, Donehower, R C, Iveson, T, Loh, E Y, Zhang, Y
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2015
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453660/
https://ncbi.nlm.nih.gov/pubmed/25584489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.649
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars